Description
[ Other Names ] 25-Hydroxyvitamin D3; 25-Hydroxycholecalciferol; Calcidiol
[ CAS No. ] 19356-17-3
[ Molecular Formula ] C27H44O2
[ Molecular Weight ] 400.64
[ Appearance ] White powder
[ Purity ] 95%~99%
[ Application ]
Calcifediol is suitable for the treatment of metabolic bone diseases such as osteoporosis, rickets, and osteomalacia, and can also be used for hypocalcemia caused by hemodialysis.
About Calcifediol
Calcifediol is transformed from vitamin D3 (VD3) in the human body under the action of VD3 hydroxylase in the liver. It is sensitive to air, heat, and light. It is easily soluble in polar organic solvents such as ethanol, but insoluble in water. Developed and marketed by Upjohn Company of the United States in the 1980s, it is used to treat various chronic bone disorders such as osteoporosis in the elderly, as well as metabolic bone diseases related to chronic renal failure.
As a highly active form of vitamin D, calcifediol is expected to break the “ceiling” of food-grade vitamin D. On July 1, 2021, the EU Nutrition, Novel Foods and Food Allergens (NDA) Research Group of the European Food Safety Authority (EFSA) issued a scientific opinion on the safety of calcifediol as a new type of food. Under certain conditions, calcifediol as a novel food is safe for individuals older than 11 years old (including pregnant and lactating women), but no conclusions can be drawn on the safety of children (3-10 years old). It is reported that the dietary supplement of calcifediol has been launched in Australia, and whether it can be listed in the huge market of the European Union may become a key factor affecting the foodization of calcifediol.
